Alliance for Aging Research on First 10 Part D Drugs Subject to Medicare Price-Setting: Today is Not a Reason to Celebrate
Retrieved on:
Wednesday, August 30, 2023
CMS, COSPAR International Reference Atmosphere, Centers for Medicare & Medicaid Services, Atrial fibrillation, Stroke, Policy, Health equity, Pharmacy, Part, Open enrollment, IRA, Government, National Council on Disability, QALY, Medicare, Martin PBM Mariner, Ageing, MHS, Congressional Budget Office, Alliance for Aging Research, H.R. 3, Disability, Patient, National Council, Economic policy of the Donald Trump administration, CBO, Presidency of Donald Trump, External, Research, Rheumatoid arthritis, Pharmaceutical industry, Health insurance
WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
Key Points:
- WASHINGTON, Aug. 29, 2023 /PRNewswire/ -- This morning, the Centers for Medicare and Medicaid Services (CMS) announced the first 10 Part D drugs to be subject to Medicare price-setting .
- Sue Peschin, MHS, President and CEO at the Alliance for Aging Research, issued the following statement in response:
The process instead captures drugs that serve large numbers of beneficiaries at modest cost rather than high-cost drugs. - "Staging a celebration to announce the first 10 Part D drugs subject to CMS' government price-setting in the Medicare program is macabre and misleading.
- We have opposed every Medicare price-setting proposal since 2019 because their value frameworks combine analyses of both cost-effectiveness and budget impact.